Stay updated on Avutometinib and Defactinib in Thyroid Cancer Clinical Trial

Sign up to get notified when there's something new on the Avutometinib and Defactinib in Thyroid Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Avutometinib and Defactinib in Thyroid Cancer Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Notably, the information regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.
    Difference
    0.9%
    Check dated 2025-07-04T04:21:37.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    The timeline for the modernization of the ClinicalTrials.gov data ingest has been updated to July 2025 from June 2025, and the revision number has changed from v2.16.2 to v2.16.4.
    Difference
    1%
    Check dated 2025-06-19T20:10:38.000Z thumbnail image
  4. Check
    26 days ago
    No Change Detected
  5. Check
    33 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T11:25:58.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T06:13:55.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T16:47:11.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a new phase II clinical trial for thyroid cancer treatments, specifically detailing the evaluation of avutometinib and defactinib for radioiodine-refractory patients. Key collaborators and the principal investigator have also been specified.
    Difference
    51%
    Check dated 2025-04-16T12:29:40.000Z thumbnail image

Stay in the know with updates to Avutometinib and Defactinib in Thyroid Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Avutometinib and Defactinib in Thyroid Cancer Clinical Trial page.